Start here if you're new
what it is
EnVVeno is building replacement vein valves for people with severe vein disease.
how it gets paid
The company is still pre-commercial: trailing product revenue rounds to $0. Any segment split here is illustrative until sales start.
what just happened
Q4 2024 EPS was -$10.49 a share.
At a glance
C++ balance sheet — some cracks in the foundation
35/100 earnings predictability — expect surprises
-$44.41 fy2024 eps est
n/m — forward revenue models vary wildly pre-revenue
1.35 beta
xvary composite: 41/100 — below average
What they do
EnVVeno is building replacement vein valves for people with severe vein disease.
The size of the problem is absurd. Chronic venous disease hits about 71% of U.S. adults. That gives your target market real scale, while the company itself has only 37 employees. Tiny team, giant problem, one lead device.
How they make money
$0
product revenue (pre-commercial) · no meaningful annual sales yet
VenoValve
$0M
Surgical replacement venous valves
$0M
Non-surgical replacement venous valves
$0M
Clinical development
$0M
The products that matter
bioprosthetic venous valve implant
VenoValve
single clinical asset · $0 trailing revenue
it is the only product that matters here, aimed at a condition affecting more than 2.5 million people in the U.S. each year. big need, zero diversification.
all or nothing
Key numbers
$7M
market cap
You are paying micro-cap prices for a company with a long road to sales.
-$44.41
fy2024 eps
That is the modeled annual loss per share (often distorted by tiny share counts and splits). Treat it as “heavy losses,” not a literal per-share cash burn rate.
n/m
fy2026 rev est
Street revenue models for pre-revenue medtech swing wildly; do not anchor a $7M cap story to one headline estimate.
1.35
beta
The stock has already told you it expects bigger swings than the market.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $0M — minimal term debt in the filing snapshot
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for NVNO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Q4 2024 EPS was -$10.49 a share.
The quarterly loss stayed ugly, even as the full-year model improved from -$66.78 in 2023 to -$44.41 in 2024. Revenue remains unavailable, which is exactly what you do not want in a public medtech story.
$0M
revenue
-$10.49
eps (q4)
-$44.41
fy2024 eps (est)
the number that mattered
The $44.41 FY2024 EPS estimate is the whole story. A company worth about $7M does not need many misses.
source: consensus + EDGAR, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is the FDA path for VenoValve staying blocked after the august 2025 not-approvable letter.
high
single-asset failure
VenoValve is the company. There is no revenue from anything else, and there is no second late-stage program to absorb a setback.
Impact: 100% of trailing revenue is already $0, so a failed path here does not trim a business. It removes the business case.
high
board versus shareholder strategy
Northstrive Fund II disclosed a 5.05% stake and wants the trial halted. If management wants to continue and a visible shareholder wants to stop, you get delay, distraction, or both.
Impact: governance conflict can matter as much as clinical risk when the company has one asset and a $7M market cap.
med
cash burn without sales
Q3 2025 net loss was $4.5M and trailing revenue is $0. Development-stage medtech burns cash by design, but thin balance-sheet strength means each quarter matters more.
Impact: if financing becomes the story, upside from eventual approval gets shared with new capital before it reaches you.
med
headline-driven volatility
The 52-week range of $9–$197 and price stability score of 5 / 100 tell you this stock does not glide. It gaps.
Impact: any filing on the FDA path, trial status, or strategic review can move the stock harder than a standard earnings release.
This risk picture exposes 100% of NVNO's operating case to one device candidate that has produced $0 in trailing revenue and already hit an FDA wall.
source: institutional data · regulatory filings · risk analysis
Pay attention to
regulatory
any clean FDA path for VenoValve
The one number that matters is still $0 revenue. That changes only if the company shows how it gets past the august 2025 not-approvable letter.
governance
whether Northstrive's 5.05% campaign gains traction
A public 13D is pressure, not noise. Watch board response, language around trial continuation, and any sign a strategic review replaces the clinical plan.
calendar
next earnings on feb 26, 2026
Losses are expected. What you need is an update on cash needs, trial status, and whether management is still backing the same path.
metric
whether revenue stays at $0 while losses keep running
Q3 2025 loss was $4.5M with no sales. If that pattern holds without regulatory progress, the capital structure becomes part of the thesis.
Analyst rankings
earnings predictability
35 / 100
in human-speak: the numbers are hard to model because one regulatory update matters more than the income statement
beta
1.35
beta measures how a stock moves versus the market. NVNO has moved more than the market, but the real driver is company-specific news.
source: institutional data
Institutional activity
institutional ownership data for NVNO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$11
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive